Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.

PURPOSE: FK506-binding protein like (FKBPL) and its peptide derivative, AD-01, have already shown tumor growth inhibition and CD44-dependent antiangiogenic activity. Here, we explore the ability of AD-01 to target CD44-positive breast cancer stem cells (BCSC). EXPERIMENTAL DESIGN: Mammosphere assays...

Full description

Bibliographic Details
Main Authors:	McClements, L, Yakkundi, A, Papaspyropoulos, A, Harrison, H, Ablett, M, Jithesh, P, McKeen, H, Bennett, R, Donley, C, Kissenpfennig, A, McIntosh, S, McCarthy, H, O'Neill, E, Clarke, R, Robson, T
Format:	Journal article
Language:	English
Published:	2013

Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.

Similar Items